Leap Therapeutics completed a $58.88 million cash private sale led by Winklevoss Capital.

robot
Abstract generation in progress

[Leap Therapeutics completes $58.88 million cash private sale led by Winklevoss Capital] Biotechnology company Leap Therapeutics (NASDAQ: LPTX) today announced that it has completed the previously announced private sale led by Winklevoss Capital, raising $58,888,888 in cash to initiate its digital asset financial strategy. Winklevoss Capital will provide funding and strategic support to help Leap build and execute its digital asset financial strategy. According to the lead investor agreement, the Leap board of directors will increase to 12 members, and Winklevoss Capital will have the right to nominate two individuals to the Leap board, one of whom will also serve as the chairperson of the board. Morgan, Lewis & Bockius LLP serves as Leap's legal advisor, while Cooley LLP serves as Winklevoss Capital's legal advisor.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)